Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy

Authors

  • H. F. Gao,

    1. State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
    Search for more papers by this author
  • Y. Liang,

    1. State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
    Search for more papers by this author
  • N. N. Zhou,

    1. State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
    Search for more papers by this author
  • D. S. Zhang,

    1. State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
    Search for more papers by this author
  • H. Y. Wu

    Corresponding author
    1. State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
    • Correspondence

      Haiying Wu, State Key Laboratory of Oncology in South China, Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, China.

      Email: nfzj1988@163.com

    Search for more papers by this author

  • Funding: None.
  • Conflict of interest: None.

Abstract

Background

Chemotherapy-induced nausea and vomiting remain among the most feared adverse effects for cancer patients.

Aim

The aim of this study was to evaluate the efficacy and safety of a combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in patients receiving multiple-day cisplatin-based chemotherapy.

Methods

Forty-one solid cancer patients received aprepitant, palonosetron and dexa- methasone during a 3-day cisplatin-based chemotherapy. Primary end-point was complete response in the overall phase (day 1 until 5 days after the end of chemotherapy).

Results

Aprepitant in combination with palonosetron and dexamethasone was safe, with hiccups (31.7%), fatigue (17.1%), headache (14.6%) and constipation (12.2%) the most common treatment-related adverse events, mostly mild. Complete response was seen in 58.5% of patients in the overall phase. In 23 patients receiving aprepitant in combination with palonosetron and dexamethasone more than one cycle (range: 2–5 cycles), the cumulative emetic protection rate after five cycles was 0.82.

Conclusion

This study shows aprepitant in combination with palonosetron and dex-amethasone is safe and effectively controls chemotherapy-induced nausea and vomiting in patients undergoing 3-day cisplatin-based chemotherapy, moreover, the efficacy is maintained during multiple cycles.

Ancillary